---
schema_version: "secwatch.filing_event.v1"
accession: "0001618835-22-000204"
form_type: "8-K"
ticker: "EVFM"
cik: "0001618835"
company_name: "Evofem Biosciences, Inc."
filed_at: "2022-11-02T23:59:59+00:00"
generated_at: "2026-06-22T14:09:24.623226+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Evofem cuts 45 jobs, suspends FY2022 guidance to conserve cash

## Summary
- Board approved reduction in force of 45 employees; completion expected by end of November 2022.
- Annualized future cost savings estimated at ~$11 million from the workforce reduction.
- Pre-tax charges of ~$0.7 million in Q4 2022 for severance and employee benefits.
- Company suspends prior fiscal year 2022 guidance due to restructuring.

## SEC filing metadata
- accession: 0001618835-22-000204
- form_type: 8-K
- ticker: EVFM
- cik: 0001618835
- company_name: Evofem Biosciences, Inc.
- filed_at: 2022-11-02T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.05, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000204/0001618835-22-000204-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000204/evfm-20221101.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001618835-22-000204
- JSON: https://secwatch.observer/filing/0001618835-22-000204.json
- Plain text: https://secwatch.observer/filing/0001618835-22-000204.txt

## Key facts
- Restructurings & Charges
  Evofem Biosciences, Inc. announced a restructuring with charges of The Company estimates that it will incur aggregate pre-tax charges of approximately $0.7 million in connection with the reduction in force, primarily consisting affecting workforce (45 employees).
  - Type: restructuring
  - Charge: The Company estimates that it will incur aggregate pre-tax charges of approximately $0.7 million in connection with the reduction in force, primarily consisting
  - Affected area: workforce
  - Headcount: 45 employees
  source text: On November 1, 2022, the Board of Directors of Evofem Biosciences, Inc. (the "Company") approved a reduction in force intended to conserve the Company's current cash resources. The Company will reduce its current workforce by 45 employees. The Company expects annualized future cost savings from the reduction in force to be approximately $11.0 million, which the Company intends to use to support its operations. The Company estimates that it will incur aggregate pre-tax charges of approximately $0.7 million in connection with the reduction in force, primarily consisting of notice period and severance payments, employee benefits and related costs. The Company expects that the reduction in force will be complete by the end of November 2022 and that these one-time charges will be incurred in the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1618835/000161883522000204/0001618835-22-000204-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.